Ronald A DePinho

This inventor holds 12 USPTO granted patents and 10 published patent applications and 2 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., The University of Texas System, University of Arkansas. Active years: 2003-2019.

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 41.7

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 65(Granted Patents)

Location History:

Boston, MA (US) (2003)
Houaton, TX (US) (2012)
Brookline, MA (US) (2012 - 2017)
Houston, TX (US) (2016 - 2019)

Company Filing History:

10 out of 1,265

Dana-Farber-Cancer Institute Inc.

patents

2 out of 5,630

The University of Texas System

patents

2 out of 849

University of Arkansas

patents

4. 1 out of 536

Beth Israel Deaconess Medical Center, Inc.

patents

5. 1 out of 1

Mietamark Genetics, Inc.

patent

6. 1 out of 3,070

The General Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 2003-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10378060 - ZNF365/ZFP365 biomarker predictive of anti-cancer response (2019-08-13),

2. 10363261 - Enolase inhibitors and methods of treatment therewith (2019-07-30),

3. 9745631 - Methods for diagnosing and treating oncogenic kras-associated cancer (2017-08-29),

4. 9687548 - Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereof (2017-06-27),

5. 9632090 - Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours (2017-04-25),

6. 9458510 - Signatures and determinants associated with prostate cancer progression and methods of use thereof (2016-10-04),

7. 9452182 - Collateral gene inactivation biomarkers and targets for cancer therapy (2016-09-27),

8. 9309564 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer (2016-04-12),

9. 8999633 - Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans (2015-04-07),

10. 8211634 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer (2012-07-03),

11. 8168602 - Compositions, kits and methods for identification, assessment, prevention and therapy of cancer (2012-05-01),

12. 6639121 - Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo (2003-10-28),

Title: The Innovative Contributions of Ronald A. DePinho

Introduction

Ronald A. DePinho is a prominent inventor based in Houston, Texas, known for his significant contributions to cancer research and treatment. With a total of 12 patents to his name, he has made remarkable strides in the field of oncology, particularly in identifying biomarkers and developing therapeutic methods.

Latest Patents

Among his latest patents is the invention of the ZNF365/ZFP365 biomarker, which is predictive of anti-cancer response. This invention is based on the identification of novel biomarkers that can help predict how patients will respond to anti-cancer therapies. Another notable patent involves enolase inhibitors and methods of treatment therewith. This patent provides compounds that inhibit enolase enzymes, including the preferential inhibition of one isoenzyme over others. These compounds can be utilized in various treatment methods, along with pharmaceutical compositions.

Career Highlights

Throughout his career, Ronald A. DePinho has worked with esteemed institutions such as the Dana-Farber Cancer Institute and the University of Arkansas. His work has been pivotal in advancing cancer research and developing innovative treatment options.

Collaborations

He has collaborated with notable colleagues, including Lynda Chin and Giovanni Tonon, contributing to a rich environment of research and innovation in cancer therapies.

Conclusion

Ronald A. DePinho's work exemplifies the impact of innovation in the medical field, particularly in cancer research. His patents and collaborations continue to influence the development of effective treatments for patients.